Introducing Clyrasept: 99.999999% Pathogen Kill in 60 Seconds and Up to 72 Hours of Ongoing Protection

AI Summary

Bullish on BioLargo (BLGO) because its 48%-owned Clyra Medical subsidiary raised capital at a ~$95M valuation and is launching ViaCLYR, which could make BLGO's stake worth far more than its <$60M market cap.

BLGO — LONG Author claims BioLargo (BLGO) is undervalued because it still owns 48% of Clyra Medical, which just raised millions at about a $95M valuation while BLGO’s entire market cap is under $60M. The catalyst is Clyra’s Clyrasept/ViaCLYR wound-irrigation launch in January 2026 and its presentation at the JAB Maui Burn & Wound Symposium on January 24–29, which the author expects to generate partnerships and adoption. If Clyra reaches the CEO-projected value north of $500M in the next year or two, BLGO’s 48% stake would make the penny-stock story look very different. Stated risk is the decade of delays and the POOPh fiasco that have weighed on the story.

Now Clyra just raised millions directly into the subsidiary at about a $95M valuation, while after the POOPh fiasco the entire BioLargo market cap is still under $60M.

Score 1

Comments 1

▶ Full Post Text

FINaLLY: 

Clyra’s Clyrasept Tech Heads to Maui: Showcasing ViaCLYR at the 2026 JAB Burn & Wound Symposium 

From their LinkedIn 

\*\*Clyra Medical Technologies\*\*

🌺 Where Innovation Meets Paradise 🌺

Ten years of research. Countless hours of testing. 38 patents. And a technology that’s about to change the conversation around infection control.

Clyra Medical Technologies is bringing our Clyrasept™ platform to the 48th Annual JAB Maui Burn & Wound Symposium this January.

Why Maui? 

Because the Boswick Symposium isn’t just another medical conference – it’s where burn and wound care innovators gather to push boundaries, challenge conventions, and improve patient outcomes together. It’s the perfect venue to introduce a technology that delivers 99.999999% effectiveness in neutralizing microbial pathogens in 60 seconds and sustains protection for 72 hours.

What we’re bringing to Maui: 

→ ViaCLYR™ for wound irrigation (launching January 2026) 

→ Clinical data that speaks for itself 

→ A team passionate about reducing infection rates.

What we hope to bring back: 

→ Partnerships with visionary clinicians 

→ Insights from global wound care leaders 

→ Stories of how Clyrasept can make a difference in patient care.

The future of infection control begins with a conversation. Let’s start it in Maui.

See you at the Wailea Beach Resort, January 24–29!

\\#Innovation #WoundCare #Boswick2026 #ClyraMedicalTechnologies #StartupJourney #HealthcareInnovation #MedicalTechnology

\*\*Why this matters:\*\* 

OP 

After many years of delay- the  launch is finally here.

CLyra medical is a BioLargo $BLGO 

subsidiary.

Clyra Medical is BioLargo’s infection‑control moonshot, and BLGO still owns 48% of it. 

This is the one the CEO was talking about when he said, “they’ll say, I guess they’re not that crazy after all.”

Shareholders have been waiting more than a decade for this moment. 

Now Clyra just raised millions directly into the subsidiary at about a $95M valuation, while after the POOPh fiasco the entire BioLargo market cap is still under $60M.

Read that again.

Some in the wound‑care world think Clyra’s tech could literally change the standard of care. 

If they’re right and the subsidiary ends up being worth north of $500M in the next year or two, (and like the CEO has projected) 

BLGO’s 48% stake suddenly makes this “penny stock” story look very different.

To learn more read my deep dive (note that a few things got delayed but are happening as we speak).

🚀 CLYRA MEDICAL ULTIMATE DD: Why This Subsidiary Inside $55M $BLGO Will Rewrite Global Wound Care 🚀

 JJ's Deep Conviction Play - From the Guy Who Called EXAS Early

https://www.reddit.com/r/pennystocks/comments/1mtw0pk/clyra\_medical\_ultimate\_dd\_why\_this\_subsidiary/

▶ Full Post Text

Ideas

More from Reddit — r/pennystocks